McLean Asset Management Corp Sells 3,076 Shares of Astrazeneca Plc $AZN

McLean Asset Management Corp trimmed its stake in Astrazeneca Plc (NYSE:AZN) by 47.4% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,418 shares of the company’s stock after selling 3,076 shares during the period. McLean Asset Management Corp’s holdings in Astrazeneca were worth $674,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in AZN. Arrowstreet Capital Limited Partnership raised its position in shares of Astrazeneca by 552.9% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 5,547,597 shares of the company’s stock valued at $973,603,000 after purchasing an additional 4,697,895 shares during the period. Pictet Asset Management Holding SA bought a new stake in shares of Astrazeneca during the 1st quarter worth $675,263,000. Bank of Montreal Can grew its stake in Astrazeneca by 344.6% in the 3rd quarter. Bank of Montreal Can now owns 3,478,114 shares of the company’s stock valued at $266,841,000 after buying an additional 2,695,793 shares during the last quarter. ABN AMRO Bank N.V. grew its stake in Astrazeneca by 32,441.5% in the 1st quarter. ABN AMRO Bank N.V. now owns 2,445,171 shares of the company’s stock valued at $482,158,000 after buying an additional 2,437,657 shares during the last quarter. Finally, Citigroup Inc. raised its holdings in Astrazeneca by 65.3% in the 4th quarter. Citigroup Inc. now owns 6,154,760 shares of the company’s stock worth $1,080,160,000 after acquiring an additional 2,431,890 shares during the period. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have weighed in on AZN. TD Cowen reissued a “buy” rating on shares of Astrazeneca in a research report on Wednesday, March 18th. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Astrazeneca in a research note on Tuesday, June 9th. UBS Group reissued a “buy” rating on shares of Astrazeneca in a research report on Friday, April 10th. Barclays restated a “buy” rating on shares of Astrazeneca in a research note on Monday, June 1st. Finally, Wall Street Zen upgraded Astrazeneca from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Twelve analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $205.33.

Astrazeneca Stock Up 0.1%

NYSE AZN opened at $188.58 on Monday. Astrazeneca Plc has a twelve month low of $137.23 and a twelve month high of $212.71. The stock has a market cap of $292.47 billion, a PE ratio of 28.32, a PEG ratio of 1.64 and a beta of 0.25. The firm has a 50-day simple moving average of $184.66 and a 200 day simple moving average of $187.16. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.71 and a current ratio of 0.91.

Astrazeneca (NYSE:AZN) last issued its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.52 by $0.06. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The firm had revenue of $15.29 billion for the quarter, compared to analyst estimates of $14.93 billion. On average, research analysts forecast that Astrazeneca Plc will post 9.39 EPS for the current year.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.